Valiant Navion胸主动脉支架系统在Valiant EVO全球临床试验中的关键结果
OBJECTIVE: The Valiant Navion stent graft system (Medtronic, Santa Rosa, Calif) is a new iteration of a thoracic endograft for the treatment of descending thoracic aortic aneurysms. Herein, the 30-day primary safety and efficacy outcomes and secondary end points are presented.…
要点
- 30天内主要器械效应发生率为2.3%,显著低于16%的性能目标。
- 无入路或释放失败,1个月内内漏发生率仅2.5%。
- 全因死亡2例,30天免于全因死亡率为97.7%。
核心结论
- Valiant Navion胸主动脉支架系统在30天内入路/释放失败、主要器械效应和内漏均罕见,结果令人鼓舞。
主要发现
- 87例患者中女性33例(37.9%),严重入路动脉扭曲61例(70.9%),高胸主动脉扭曲66例(85.7%)。
- 平均手术时间88.7±53.4分钟,美国站点经皮入路37/52(71.2%),美国外站点外科切开28/35(80.0%)。
- 无入路或释放失败,30天内主要器械效应发生率2.3%(2/87;P<.0001;性能目标16%)。
- 需二次手术2例(1例逆行A型夹层,1例主动脉弓破裂),30天内死亡2例,免于全因死亡率97.7%。
- 1个月时内漏发生率2.5%(1例Ia型,1例II型)。
临床怎么用
- 该30天结果提示Valiant Navion支架系统在胸主动脉瘤腔内治疗中早期安全性良好,但需5年长期随访验证。
局限性
- 本研究为单臂试验,缺乏对照组,且随访仅报告30天结果,长期疗效待确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The Valiant Navion stent graft system (Medtronic, Santa Rosa, Calif) is a new iteration of a thoracic endograft for the treatment of descending thoracic aortic aneurysms. Herein, the 30-day primary safety and efficacy outcomes and secondary end points are presented. METHODS: The Valiant EVO global clinical trial is a prospective, nonrandomized, single-arm trial. Patient enrollment occurred from April 2016 to October 2017. The primary end point was defined as access and/or deployment failure and/or a major device effect (MDE), including device-related secondary procedures, device-related mortality, conversion to open surgery, or thoracic aortic aneurysm rupture within 30 days of the index procedure. Other measures of stent graft performance including procedural data, rates of secondary procedures, and frequency of endoleaks are also reported. RESULTS: Of the 87 consecutive patients undergoing thoracic endovascular aneurysm repair who were enrolled, 33 (37.9%) were female with 61 (70.9%) presenting with severe access artery tortuosity and 66 (85.7%) with high thoracic aortic tortuosity per core laboratory evaluation. The mean procedure duration was 88.7 ± 53.4 minutes and geographical differences existed such as percutaneous access (37/52 [71.2%]) in the United States and surgical cut down in the outside of the U.S. sites (28/35 [80.0%]). There were no access or deployment failures and only 2.3% of the patients (2/87; P < .0001; performance goal of 16%) experienced a MDE within 30 days of the index procedure. Two secondary procedures (n = 1 retrograde type A dissection; n = 1 aortic arch rupture) were required, and in the first 30 days, two patients died leading to a freedom from all-cause mortality of 97.7%. Endoleaks at 1 month were reported in 2.5% of patients (n = 1 type Ia; n = 1 type II). CONCLUSIONS: Access/deployment failures, MDEs, and endoleaks were rare in the first 30 days of the Valiant Evo clinical trial. The Valiant Navion thoracic stent graft system has shown encouraging 30-day results in this challenging cohort and trial patients will continue to be followed through 5 years.
引用
- Azizzadeh A, Desai N, Arko FR, et al. Pivotal results for the Valiant Navion stent graft system in the Valiant EVO global clinical trial. J Vasc Surg. 2019. PMID: 31126765. doi:10.1016/j.jvs.2019.01.067
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。